Our data raise concerns regarding targeting the FASN/ERα signalling pathway in ERα-positive breast cancers as inhibiting them enhanced the invasive potential of the cells via a novel caveolin-1-dependent mechanism. The gene discussed is ESR1; the disease is breast cancer.